21
Participants
Start Date
February 28, 2007
Primary Completion Date
December 31, 2008
Study Completion Date
March 31, 2009
SNS-032 Injection
"Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle~Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1"
Greenebaum Cancer Center, University of Maryland, Baltimore
Winship Cancer Institute at Emory University, Atlanta
MD Anderson Cancer Center, University of Texas, Houston
City of Hope, Duarte
Stanford Cancer Center, Stanford
Hackensack University Medical Center at the Cancer Center, Hackensack
Lead Sponsor
Sunesis Pharmaceuticals
INDUSTRY